- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02447640
PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration
An Open Label PET Imaging Study to Evaluate the mGlu5 Receptor Occupancy Following ADX48621 (Dipraglurant) Administration
Study Overview
Detailed Description
This is an open label study, non-randomized, positron emission tomography (PET) study investigating mGlu5 receptor occupancy after single or two oral dosing of ADX48621 in healthy subjects using [18F]-FPEB . The study consists of 2 parts.
Part 1: A receptor occupancy dose curve will be obtained by using an adaptive design. Subjects will undergo two [18F]-FPEB PET imaging sessions: a baseline plus a scan after treatment with one dose of ADX48621. The second scan will be taken at Tmax for ADX48621 (1 hour post dose). 100 mg will be the initial dose as this has been proven to be efficacious in a P2A study in Parkinson's patients. This is an open label study, non-randomized, positron emission tomography (PET)study investigating mGlu5 receptor occupancy after single or two oral dosing of ADX48621 in healthy subjects using [18F]-FPEB as the radiotracer.The maximum dose to be given will be 200 mg.
Part 2: The time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1. Two subjects will receive 2 doses of ADX48621 on 2 separate days and undergo three [18F]-FPEB PET imaging sessions: a baseline scan, post dose scan 1 and post dose scan 2. Subjects will be given ADX48621 one hour prior post dose scan 1. The 2nd dose will be given in the morning approximately 4-6 hours prior of the post dose scan 2. The post dose scan 2 will be performed in the afternoon. The maximum dose to be given will be 400 mg.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males and females, 18-60 years old
- BMI of 18-32 kg/m2
- Female subjects must meet one of the following criteria:Surgically sterile (e.g. hysterectomy, or bilateral oophorectomy, tubal ligation) for at least 6 months prior to screening or Postmenopausal (no menstrual bleeding for at least 1 year prior to screening and confirmed by a plasma FSH level of > 40 IU/L) or Non-pregnant, non- lactating women of child-bearing potential and practicing contraception (e.g. hormonal birth control, intra uterine device, condom and spermicide)
- Able to comprehend and willing to sign an Informed Consent Form (ICF).
Exclusion Criteria:
- Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or any psychiatric disorder (as determined by the Investigator).
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (except that appendectomy and hernia repair will be allowed).
- Use of any tobacco-containing or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to consent.
- Poor peripheral venous access.
- Participation in any clinical drug study within 30 days prior to dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1
A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
|
ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
Other Names:
radiotracer used for PET scanning
|
Experimental: Part 2
In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
|
ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
Other Names:
radiotracer used for PET scanning
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome will be the maximum receptor occupancy and EC 50 for the receptor occupancy/ADX48621 plasma concentration relationship
Time Frame: During Day 1 PET scan
|
This is composite
|
During Day 1 PET scan
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dean F Wong, MD,PhD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ADX48621-104
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on ADX48621
-
Addex Pharma S.A.RecruitingDystonia | BlepharospasmUnited States
-
Addex Pharma S.A.RecruitingParkinson Disease | Dyskinesias | Dyskinesia, Drug-InducedUnited States
-
Addex Pharma S.A.CompletedParkinson's DiseaseUnited States, Austria, France, Germany
-
Addex Pharma S.A.RecruitingParkinson Disease | Dyskinesias | Dyskinesia, Drug-InducedUnited States